UNIverse - Public Research Portal
Project cover

The risk of rosacea in patients with inflammatory bowel diseases

Research Project
 | 
01.01.2015
 - 01.01.2016

BACKGROUND: Cutaneous manifestations are common in patients with inflammatory bowel diseases (IBDs) (ulcerative colitis [UC] and Crohn's disease [CD]). Previous case reports described patients with IBD who developed rosacea . IBD and rosacea are inflammatory epithelial diseases, presumably associated with changes in the innate immune system. We explored the association between IBD and incident rosacea . METHODS: We conducted a population-based matched (1:1) case-control analysis on the association between IBD and rosacea , stratified by IBD disease duration and severity. We used data from the UK-based Clinical Practice Research Datalink. Cases had an incident diagnosis of rosacea recorded between 1995 and 2013. RESULTS: Among 80,957 rosacea cases and the same number of controls, a history of UC was associated with an increased risk of rosacea (odds ratio [OR] 1.65, 95% confidence interval [CI], 1.43-1.90), with the highest OR in those with short UC duration (OR 2.85, 95% confidence interval, 1.80-4.50 for patients with <2 years of disease history). A history of CD yielded an overall OR of 1.49 (95% CI, 1.25-1.77), which did not correlate with disease duration. Additional analyses on IBD disease severity yielded evidence for a higher risk of rosacea in those with higher UC and CD activity. CONCLUSIONS: Our findings provide evidence that patients with IBD may be at increased risk of rosacea (higher in UC), particularly during phases of increased IBD-associated gastrointestinal tract inflammation.

Publications

Spoendlin, Julia et al. (2016) ‘Rosacea in Patients with Ulcerative Colitis and Crohn’s Disease: a Population-based Case-control Study’, Inflammatory Bowel Diseases, 22(3), pp. 680–687. Available at: https://doi.org/10.1097/mib.0000000000000644.

URLs
URLs

Members (2)

MALE avatar

Christoph R. Meier

Principal Investigator
Profile Photo

Julia Spöndlin

Principal Investigator